Ivacaftor
Back to searchMolecule Structure
Scientific Name
Ivacaftor
Description of the Drug
Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator used alone or in combination products to treat cystic fibrosis in patients who have specific genetic mutations that are responsive to the medication.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08820
http://www.drugbank.ca/drugs/DB08820
Brand Name(s)
Kalydeco
Company Owner(s)
Vertex Pharmaceuticals Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Cystic fibrosis transmembrane conductance regulator | SINGLE PROTEIN | POSITIVE MODULATOR | CHEMBL4051 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL351373 | |
PharmGKB | PA165950341 | |
Human Metabolome Database | HMDB0015705 | |
DrugBank | DB08820 | |
PubChem: Thomson Pharma | 24902571 | |
PubChem | 16220172 | |
LINCS | LSM-45975 | |
Nikkaji | J3.163.539J | |
PDBe | VX7 | |
BindingDB | 50032693 | |
EPA CompTox Dashboard | DTXSID00236281 | |
DrugCentral | 4228 | |
ChemicalBook | CB32506174 | |
Guide to Pharmacology | 4342 | |
rxnorm | IVACAFTOR | KALYDECO |
PubChem: Drugs of the Future | 125299328 | |
ChEBI | 66901 | |
ZINC | ZINC000052509463 |